Albumedix: A world leader within recombinant albumin engineering




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Albumedix: A world leader within recombinant albumin engineering
Released on: August 10, 2016. © PharmaVentures Ltd
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    Albumedix, a spinout from Novozymes, develops albumin-based products and technologies for advanced drug and vaccine formulation.
  • Summary
  • Participants
  • Company
Albumedix, a spinout from Novozymes, develops albumin-based products and technologies for advanced drug and vaccine formulation. Talking with Adrian Dawkes at the Anglo Nordic Life Science Conference 2016, Dave Mead discusses business partnerships and Recombumin®, the world's first and only supply of commercial recombinant human albumin, approved for use in the manufacture of human therapeutics.
Dave Mead, Director, Business Development, Albumedix
Albumedix develops albumin-based products and technologies for advanced drug and vaccine formulation, extended drug half-life and improved drug delivery. Our products and technologies are used in clinical and marketed drugs and out-licensed to pharmaceutical and biotech companies worldwide. With over 25 years’ experience in the biopharmaceutical industry, we have the scientific, technical and regulatory expertise needed to support companies in moving faster to market with superior biotherapeutics. We also use this expertise to strengthen our own drug pipeline. Albumedix is a global company and a fully owned subsidiary of Novozymes A/S